SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) JUNE 24, 1996

ENZON, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	0-12957	22-237286
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification)

20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (908) 980-4500

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

Enzon, Inc. ("Enzon" or the "Company") announced that a multi-dose, multi-center clinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin, has begun in cancer patients receiving radiation therapy. Patients entering this new trial will receive once-a-week infusions of PEG-hemoglobin followed by five days of radiation treatment. This will be repeated weekly for three weeks. The primary purpose of this trial is to evaluate safety related to multiple doses of PEG-hemoglobin in patients. It also offers an opportunity to observe tumor responses in patients receiving the combination of PEG-hemoglobin and radiation therapy. To date, as many as three injections of PEG-hemoglobin have been administered to patients participating in this clinical trial.

In a previous Phase I safety trial, completed at the end of 1995, 34 normal volunteers received a single dose of PEG-hemoglobin in amounts up to the equivalent of 1.5 units of whole blood. The dose levels in the new trial will be approximately one-half to two-thirds of the highest dose used in the previous Phase I safety trial. The Company believes that, at this dose level, a sufficient amount of PEG-hemoglobin will remain in the blood stream to increase tumor oxygenation during most of each five-day treatment cycle.

Enzon continues to dedicate its pilot manufacturing capability exclusively to the production of PEG-hemoglobin for additional clinical materials and commercial process development. The existing facility at the present scale is adequate to supply all PEG-hemoglobin needed for clinical trials.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 22, 1996

ENZON, INC.
(Registrant)

By: /s/KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer